Vasopressin is typically added when a patient with septic shock cannot maintain adequate blood pressure despite an initial vasopressor. The 2021 Surviving Sepsis Campaign guidelines recommend adding vasopressin when norepinephrine alone fails to achieve a mean arterial pressure (MAP) of 65 mmHg, rather than continuing to escalate the norepinephrine dose. This is a weak recommendation based on moderate-quality evidence, which means clinical judgment still plays a significant role in the decision.
The Trigger for Adding Vasopressin
Norepinephrine is the first-line vasopressor in septic shock, and the initial goal is reaching a MAP of 65 to 70 mmHg. When norepinephrine alone can’t get there, the question becomes whether to keep increasing the dose or bring in a second agent. The current expert consensus favors adding vasopressin at that point, a strategy sometimes called “decatecholaminization,” because it reduces the total burden of catecholamine-based drugs on the heart and blood vessels.
There is no single norepinephrine dose that universally triggers the switch. Some clinicians add vasopressin relatively early, while others wait until norepinephrine reaches higher ranges. What the guidelines emphasize is the principle: if MAP remains inadequate, add vasopressin rather than pushing norepinephrine further. At very high norepinephrine doses (at or above 1 microgram per kilogram per minute), the case for adding a second agent becomes even stronger, though many clinicians act well before that threshold.
The MAP target itself may need to be individualized. Patients with a history of chronic high blood pressure, for example, may need a higher target than 65 mmHg to maintain adequate organ perfusion.
How Vasopressin Works Differently
Vasopressin is a natural hormone released by the pituitary gland. It constricts blood vessels through a completely different pathway than norepinephrine. While norepinephrine works through adrenergic receptors, vasopressin activates V1a receptors on smooth muscle cells, causing them to contract and raise blood pressure. In healthy people this effect is minimal, but in septic shock, where the body’s own vasopressin stores become depleted, supplementing it can meaningfully restore vascular tone.
This separate mechanism is the whole rationale for combining the two drugs. They work through independent receptor systems, so using both can achieve blood pressure targets that neither could reach alone, while keeping the dose of each lower than it would need to be as a solo agent.
What the Major Trials Found
The landmark VASST trial, published in the New England Journal of Medicine, randomized 778 patients with septic shock to receive either vasopressin or additional norepinephrine. Overall, vasopressin did not significantly reduce mortality: 28-day death rates were 35.4% in the vasopressin group versus 39.3% in the norepinephrine group. The difference was not statistically significant.
However, a pre-planned subgroup analysis told a more nuanced story. Among patients with less severe septic shock, those receiving vasopressin had a 28-day mortality rate of 26.5% compared to 35.7% with norepinephrine alone. This suggests that adding vasopressin earlier, before shock becomes refractory, may offer a survival advantage. In patients with more severe shock, there was no meaningful difference between the two groups.
The VANISH trial looked at a different outcome and found that patients who received vasopressin were less likely to need dialysis. Renal replacement therapy was required in 25.4% of the vasopressin group compared to 35.3% of the norepinephrine group, a nearly 10 percentage point difference. This kidney-protective effect is one of the more consistent findings across vasopressin research and may factor into clinical decision-making, particularly for patients with early signs of kidney stress.
Interaction With Corticosteroids
Vasopressin and corticosteroids like hydrocortisone are both commonly used as adjunctive therapies in septic shock, and they appear to interact in a clinically meaningful way. A pilot trial of 61 patients found that those receiving both vasopressin and hydrocortisone needed vasopressin for a shorter duration (about 3 days less) and required roughly half the total vasopressin dose compared to those on vasopressin alone. This suggests that when corticosteroids are already part of the treatment plan, vasopressin may work more efficiently, though the exact mechanism behind this interaction is still being studied.
Safety Concerns to Watch For
The major clinical trials found no significant difference in serious ischemic complications (gut ischemia, heart attacks, or strokes) between vasopressin and norepinephrine groups. The one consistent signal is digital ischemia, where reduced blood flow causes damage to the fingers or toes. Two meta-analyses have confirmed a link between vasopressin use and higher rates of digital ischemia. This risk appears to be dose-related and is more pronounced with vasopressin analogues like terlipressin, where digital ischemia occurred in 13% of patients compared to 0.35% with norepinephrine in one trial.
Monitoring extremities for signs of poor circulation is a standard part of care when vasopressin is running. The drug’s short half-life is a practical advantage here: if problems develop, reducing or stopping the infusion produces a relatively quick response.
Weaning Vasopressors During Recovery
When a patient begins improving, the order in which vasopressors are tapered matters. Recent evidence suggests that weaning vasopressin first, while continuing norepinephrine, may lead to better outcomes. In one study, patients whose vasopressin was stopped before norepinephrine had a shorter duration of mechanical ventilation (median of 4 days) and significantly lower odds of death, with an adjusted odds ratio of 0.30. This is a meaningful difference, though the finding still needs validation in larger trials.
The practical takeaway is that vasopressin is generally treated as the add-on agent: started second and stopped first, with norepinephrine serving as the backbone vasopressor throughout the course of septic shock management.